no comment?

As a shareholder, potential investors may act with caution over this and the fact Helen wouldn't comment on the matter.[I know people want to put it to rest, but to be frank, no 1 is talking about anything and as shareholders our job is to hold the board to account]

CBIO CEO HELEN CAMERON SELLS SHARES
CBIO
CBio interim chief executive officer Helen Cameron sold 238,421 shares in her company
for $38,598 on December 12 and 13, 2011.
In her Appendix 3Y director’s interest statement, Ms Cameron said she held 448,000
shares prior to the sale, reducing her holding by 53.2 percent.
On December 16, 2011, CBio said Novo Nordisk did not take up its option to continue
development of XToll for rheumatoid arthritis, which followed the phase IIa trial failing to
meet its primary endpoint (BD: Aug 1, Dec 16, 2011).
Biotech Daily contacted Ms Cameron but she declined to comment.